Pharsight

Eprontia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11911362 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11826343 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11633374 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

Eprontia is owned by Azurity.

Eprontia contains Topiramate.

Eprontia has a total of 4 drug patents out of which 0 drug patents have expired.

Eprontia was authorised for market use on 05 November, 2021.

Eprontia is available in solution;oral dosage forms.

Eprontia can be used as indicated for the preventive treatment of migraine in patients 12 years and older.

The generics of Eprontia are possible to be released after 21 August, 2040.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date:

05 November, 2021

Treatment:

Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage:

SOLUTION;ORAL

How can I launch a generic of EPRONTIA before its drug patent expiration?

More Information on Dosage

EPRONTIA family patents

Family Patents